Oculis to buy Accure rights to Privosegtor for $3.8 million plus up to 2,050,000 shares
Reuters2026/08/10 07:02- Oculis signed an asset purchase agreement to buy Accure’s worldwide development and commercial rights to Privosegtor (ACT-01).
- Deal would terminate the existing Privosegtor license, removing related milestone payments and royalties; Oculis would retain greater economics on future sales.
- Consideration: USD 3.8 million cash upfront at first closing; up to 2,050,000 Oculis ordinary shares, including milestone-based earnout shares.
- Transaction also includes a separate, later closing for ACT-02, an early-stage preclinical neurology candidate, contingent on the Privosegtor closing.
- Privosegtor closing expected by Feb. 28, 2027; ACT-02 closing expected by March 31, 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fitch "shows mercy" and maintains France's A+ rating, but warns that uncontrolled deficits could lead to a downgrade
Fitch Ratings recently announced that it is maintaining France's sovereign credit rating at "A+" with a "stable" outlook, even though the agency has once again warned that sustained fiscal deficits and rising public debt amidst increasing political uncertainty could still trigger a future rating downgrade.
Here’s Why XRP Price Just Crashed Sharply
What Can We Expect from Bitcoin (BTC) and Dogecoin (DOGE) Prices in the Coming Days?
BTC Recovers From Sub-$77K Dip, XRP Drops Below $1.40: Weekend Watch
Crypto prices
More
